

INVITATION

24 October 2024

COSTEM 2024: THERAKOS MEET THE EXPERT SESSION

Hotel nhow Berlin, Germany

This information is intended for healthcare professionals based in Europe and the Middle East.

Agenda

Time: 18:00 – 18:30 CET

-
- | | |
|---------------|---|
| 18:00 – 18:15 | ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD
Prof. Nicolaus Kröger , University Medical Center Hamburg-Eppendorf, Germany |
| 18:15 – 18:20 | Q&A |
| 18:20 – 18:30 | Announcement of the winner of the Mallinckrodt 2024 Advancing ECP Immunomodulation Investigator Award: 30 Years of ECP in Graft versus Host Disease. Refining THERAKOS ECP Immunomodulation™ |

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease

Speaker subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

[Privacy policy](#)

Follow the
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2024 Mallinckrodt. EU-2400070 March 2024.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.